Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inder Anand

Showing results (11-20 of 110) with videos related to

Pageof 11
Sort By:
Journal of Cardiac Failure|February 26, 2005
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practiceAldo P Maggioni, Cristina Opasich, Inder Anand, et al.
Journal of the American College of Cardiology|June 3, 2004
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Lancet (London, England)|July 28, 2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialInder Anand, John McMurray, Jay N Cohn, et al.
Circulation|June 24, 2004
Anemia and its relationship to clinical outcome in heart failureInder Anand, John J V McMurray, James Whitmore, et al.
The American Journal of Cardiology|May 22, 2014
Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure TrialKeith Copelin Ferdinand, Uri Elkayam, Donna Mancini, et al.
International Journal of Cardiology. Heart & Vasculature|June 9, 2020
Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fractionInder Anand, Jeffrey L Ardell, Doug Gregory, et al.
European Journal of Heart Failure|December 15, 2006
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure TrialMariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 10, 2013
Impact of renal dysfunction on the Seattle Heart Failure ModelKairav P Vakil, Todd Dardas, Sunil Dhar, et al.
Plos One|April 9, 2010
Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failureAndrea Kuenzli, Heiner C Bucher, Inder Anand, et al.
Circulation. Heart Failure|August 14, 2013
Race influences the safety and efficacy of spironolactone in severe heart failureOrly Vardeny, Larisa H Cavallari, Brian Claggett, et al.
Pageof 11

Showing results (11-20 of 110) with videos related to

Sort By:
Pageof 11
Journal of Cardiac Failure|February 26, 2005
Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practiceAldo P Maggioni, Cristina Opasich, Inder Anand, et al.
Journal of the American College of Cardiology|June 3, 2004
Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic dataMaylene Wong, Lidia Staszewsky, Roberto Latini, et al.
Lancet (London, England)|July 28, 2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trialInder Anand, John McMurray, Jay N Cohn, et al.
Circulation|June 24, 2004
Anemia and its relationship to clinical outcome in heart failureInder Anand, John J V McMurray, James Whitmore, et al.
The American Journal of Cardiology|May 22, 2014
Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure TrialKeith Copelin Ferdinand, Uri Elkayam, Donna Mancini, et al.
International Journal of Cardiology. Heart & Vasculature|June 9, 2020
Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fractionInder Anand, Jeffrey L Ardell, Doug Gregory, et al.
European Journal of Heart Failure|December 15, 2006
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure TrialMariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 10, 2013
Impact of renal dysfunction on the Seattle Heart Failure ModelKairav P Vakil, Todd Dardas, Sunil Dhar, et al.
Plos One|April 9, 2010
Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failureAndrea Kuenzli, Heiner C Bucher, Inder Anand, et al.
Circulation. Heart Failure|August 14, 2013
Race influences the safety and efficacy of spironolactone in severe heart failureOrly Vardeny, Larisa H Cavallari, Brian Claggett, et al.
Pageof 11